Gut Liver.
2012 Jul;6(3):339-343.
Effects of the Oral Administration of Mosapride Citrate on Capsule Endoscopy Completion Rate
- Affiliations
-
- 1Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- 2Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan. hogata@z8.keio.jp
- 3Department of General Internal Medicine, Saitama Medical University, Saitama, Japan.
- 4Department of Gastroenterology, Tokyo Medical and Dental University School of Medicine, Tokyo, Japan.
Abstract
- BACKGROUND/AIMS
In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion.
METHODS
In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time.
RESULTS
The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT).
CONCLUSIONS
Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.